Dr. Nathan W. Bartlett is Associate Professor and head of the Viral Immunology and Respiratory Disease group, based at the Hunter Medical Research Institute (HMRI), University of Newcastle, Australia. He also retains an honorary academic appointment at the National Heart and Lung Institute, Imperial College London, UK. He has over 20 years of experience working in respiratory viral immunology, pathogenesis of virus induced respiratory diseases and drug and vaccine development. After completing Post-Doctoral Research, first at the University of Oxford and then Imperial College London, he developed a research program investigating rhinovirus infections and exacerbations of asthma and COPD. His expertise across pre-clinical respiratory virus infection models (including primary human airway epithelial cells) has led him collaborate on multiple projects generating several patents and numerous highly cited publications. His team is exploring a range of anti-viral and vaccine approaches for SARS-CoV-2 and respiratory viruses including a TLR2/6 agonist-based nasal spray (with ENA Respiratory) that is currently in phase 2 clinical trial for influenza virus infection. Dr Bartlett currently advises for ENA Respiratory, Lanier Therapeutics, Foray Therapeutics and is spokesperson for the National Asthma Council. He is a member of the European Respiratory Society College of Experts and Deputy Director of the Priority Research Centre for Healthy Lungs (University of Newcastle). In addition to research, Dr. Bartlett is actively engaged in undergraduate teaching and mentoring Year 1 and 2 Medicine students, Biomedical Science students as well as supervising multiple PhD students.